Acute ketamine induces neuronal hyperexcitability and deficits in prepulse inhibition by upregulating IL-6

Prog Neuropsychopharmacol Biol Psychiatry. 2024 Mar 2:130:110913. doi: 10.1016/j.pnpbp.2023.110913. Epub 2023 Dec 14.

Abstract

Acute ketamine administration results in psychotic symptoms similar to those observed in schizophrenia and is regarded as a pharmacological model of schizophrenia. Accumulating evidence suggests that patients with schizophrenia show increased IL-6 levels in the blood and cerebrospinal fluid and that IL-6 levels are associated with the severity of psychotic symptoms. In the present study, we found that a single ketamine exposure led to increased expression of IL-6 and IL-6Rα, decreased dendritic spine density, increased expression and currents of T-type calcium channels, and increased neuron excitability in the hippocampal CA1 area 12 h after exposure. Acute ketamine administration also led to impaired prepulse inhibition (PPI) 12 h after administration. Additionally, we found that the expression of signaling molecules IKKα/β, NF-κB, JAK2, and STAT3 was upregulated 12 h after a single ketamine injection. The decreases in dendritic spine density, the increases in calcium currents and neuron excitability, and the impairments in PPI were ameliorated by blocking IL-6 or IL-6Rα. Our findings show that blocking IL-6 or its receptor may protect hippocampal neurons from hyperexcitability, thereby ameliorating ketamine-induced psychotic effects. Our study provides additional evidence that targeting IL-6 and its receptor is a potential strategy for treating psychotic symptoms in acute ketamine-induced psychosis and schizophrenia.

Keywords: Calcium channels; IL-6; Ketamine; Neuron excitability; Schizophrenia.

MeSH terms

  • Humans
  • Interleukin-6
  • Ketamine* / pharmacology
  • Ketamine* / therapeutic use
  • Prepulse Inhibition
  • Psychotic Disorders*
  • Schizophrenia* / drug therapy
  • Schizophrenia* / metabolism

Substances

  • Ketamine
  • Interleukin-6